Spero Therapeutics Announces Third Quarter 2024 Operating Results and Provides a Business Update
14. November 2024 16:05 ET
|
Spero Therapeutics, Inc.
Phase 3 PIVOT-PO trial of tebipenem HBr remains on track to complete enrollment in 2H 2025 Reiterate cash runway into mid-2026; Q3 2024 ending cash balance of $76.3M CAMBRIDGE,...
Spero Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 14, 2024
07. November 2024 16:05 ET
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel...
Spero Therapeutics Announces SPR720 Phase 2a Interim Results and Provides a Business Update
29. Oktober 2024 16:05 ET
|
Spero Therapeutics, Inc.
Phase 2a proof-of-concept study of SPR720 for the treatment of Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD) did not meet its primary endpoint, based on planned interim analysis of 16...
Spero Therapeutics Announces Presentation of SPR719 (Active Moiety of SPR720) In Vitro Data Demonstrating Low Propensity for the Development of Resistance at IDWeek 2024
16. Oktober 2024 16:05 ET
|
Spero Therapeutics, Inc.
In vitro data on SPR719 show low propensity for resistance development in NTM-PD MAC strains when administered as a single agent and in combination with standard of care agents Study highlighting...
Spero Therapeutics Announces Publication of SPR720 Phase 1 Lung Exposure Data in Antimicrobial Agents and Chemotherapy
02. Oktober 2024 16:30 ET
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel...
Spero Therapeutics to Present at Upcoming September Investor Conferences
04. September 2024 16:05 ET
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and...
Spero Therapeutics Announces Second Quarter 2024 Operating Results and Provides a Business Update
05. August 2024 16:01 ET
|
Spero Therapeutics, Inc.
Enrollment concluded in the Phase 2a proof-of-concept clinical trial evaluating SPR720 in nontuberculous mycobacterial pulmonary disease (NTM-PD); preliminary data expected in 4Q 2024New SPR720...
Spero Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update on Monday, August 5, 2024
29. Juli 2024 16:05 ET
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., July 29, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel...
Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
03. Juli 2024 13:05 ET
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., July 03, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel...
Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
03. Juni 2024 16:05 ET
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., June 03, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel...